CBPO - China Biologic Products Holdings, Inc.
| Previous Close | 97.19 |
| Open | 96.99 |
| Bid | 96.99 x 800 |
| Ask | 97.07 x 1400 |
| Day's Range | 96.78 - 97.90 |
| 52 Week Range | 60.08 - 107.44 |
| Volume | 207,229 |
| Avg. Volume | 236,180 |
| Market Cap | 3.82B |
| Beta (3Y Monthly) | 0.75 |
| PE Ratio (TTM) | 27.49 |
| EPS (TTM) | 3.53 |
| Earnings Date | May 2, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 88.55 |
- Zacks•12 days ago
New Strong Sell Stocks for April 9th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- Markit•19 days ago
See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CBPO are favorable, with net inflows of $241 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•last month
New Strong Sell Stocks for March 22nd
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•last month
New Strong Sell Stocks for March 18th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Motley Fool•last monthChina Biologic Products Inc (CBPO) Q4 2018 Earnings Conference Call Transcript
CBPO earnings call for the period ending December 31, 2018.
- PR Newswire•last month
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018
-- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million ; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total Sales ...
- PR Newswire•2 months ago
China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results
BEIJING , Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Insider Monkey•2 months ago
Dalton Investments’ Return, AUM, and Holdings
Exactly 30 years ago, Steve Persky, James Rosenwald, and Gifford Combs joined together to form Dalton Investments, a Santa Monica – based hedge fund. What made these three businessmen join together as a team was a serious investment experience in Asia and a vision of an investment management firm with a main focus on the […]
- PR Newswire•3 months ago
China Biologic Reiterates Full Year 2018 Financial Forecast
BEIJING, Jan. 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its previously revised full year 2018 forecast. Full year 2018 non-GAAP adjusted income from operations is expected to increase in the range of 0% to 2% in RMB terms and non-GAAP adjusted net income is expected to decrease by 2% to 4% in RMB terms over full year 2017 financial results. Excluding TianXinFu, full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.
- Business Wire•4 months ago
David Gao Issues Statement Following Decision by the Grand Court of the Cayman Islands
“I am disappointed that my lawsuit was dismissed and will evaluate all options as I continue my efforts to protect my and other minority shareholders’ interests in the company. “It is unfortunate that the legal process is hindered because of a Cayman law technicality with regard to my standing to file such a lawsuit before the court can hear the substance of the case regarding the improper purpose of the Board’s actions. The Board’s hastily arranged private placement to a small group of handpicked investors, including Centurium Capital, Chairman David Li’s private equity fund, improperly transferred voting power away from the minority shareholders.
- PR Newswire•4 months ago
China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman
BEIJING , Dec. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) (" China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- ACCESSWIRE•4 months ago
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
- Associated Press•6 months ago
China Biologic Products: 3Q Earnings Snapshot
On a per-share basis, the Beijing-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to 96 cents per share. The biopharmaceutical company posted revenue of $119.1 ...
- PR Newswire•6 months ago
China Biologic Reports Financial Results for the Third Quarter of 2018
3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Di rectors Ap proves $100 ...
- PR Newswire•6 months ago
China Biologic Products to Report Third Quarter 2018 Financial Results
BEIJING , Oct. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
